Astel­las los­es patent in­fringe­ment case over block­buster blad­der drug

Astel­las just faced a set­back in fed­er­al court — with a judge in­val­i­dat­ing three claims on a patent sur­round­ing an ex­tend­ed re­lease ver­sion of its block­buster over­ac­tive blad­der drug.

The four-page rul­ing was hand­ed down Fri­day in the US Dis­trict Court in the Dis­trict of Delaware. The case cen­ters around Astel­las’ Myr­be­triq (mirabegron), which made over $1.3 bil­lion in sales last year and was ap­proved by the FDA in 2012.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.